The Dish’s Weekly Biotechnology News Wrap Up – July 8, 2016
This week’s biotechnology news headlines include, California drug price plan criticized, AstraZeneca sells two dermatology rights to LEO Pharma, FDA issues new draft guidance on elemental impurities, NICE backs Ferring’s Firmagon, MIT startup nabs $30M for first 3D printed drug approved by FDA, unmasking Alzheimer’s risk in young adults, and men with advanced prostate cancer might consider gene test.
Cell Culture Events
Webinars:
Bioprocess Insights Webinars
The biopharmaceutical industry has developed into a multi-billion dollar market in just 30 years. Making decisions and setting up strategies in a rapidly changing environment can be challenging. The difference between a good and a great decision can have extensive implications for the future of a company. In this environment, knowledge and experience are what make the difference. Good insights about, for example, technical advancements, process economy implications, and sustainability aspects can help improve the individual decisions and strengthen the overall business strategy.
In this webinar series, four renowned subject matter experts will share their insights into four areas of bioprocessing: upstream, vaccines, downstream, and single-use technology. We will present tangible, recently developed data that can help you in developing modern, cost-efficient, and sustainable bioprocesses.
Don’t miss these on demand webinars – http://www.bioprocessintl.com/sponsored-content/bioprocess-insights-webinars/
Headlines:
“California Drug Price Plan Is Criticized by Patient Advocates,” The New York Times
“A state ballot initiative meant to lower prescription drug prices for California faces an expected opponent: the pharmaceutical industry, which has spent almost $70 million to defeat it.”
If you like this story, please see our blog titled “Poster: Convert your glass benchtop bioreactors to single-use with minimal capital investment”
“AstraZeneca sells two dermatology drug rights to LEO Pharma,” Reuters
“British drugmaker AstraZeneca Plc said it sold the rights to develop an experimental mid-stage drug to treat atopic dermatitis to privately-held LEO Pharma.”
If you like this story, please see our blog titled “Cool Tool – Clarification using Acoustic Wave Separation offers Advantages including -Continuous Process Solution”
“FDA Issues New Draft Guidance on Elemental Impurities,” Regulatory Focus
“The US Food and Drug Administration (FDA) on Thursday issued new draft guidance on elemental impurities in drugs, with the goal of helping manufacturers comply with recent International Council for Harmonisation (ICH) and United States Pharmacopeial Convention (USP) standards.”
If you like this story, please see our blog titled “Gene Therapy Strengthened by Recent Successes”
“NICE backs Ferring’s Firmagon,” PharmaTimes
“Men with advanced hormone-dependent prostate cancer and spinal metastases are to gain routine access to Ferring’s Firmagon on the NHS after a u-turn by the National Institute for Health and Care Excellence saw the cost regulator issue final draft guidance endorsing its use.”
If you like this story, please see our blog titled “Cell Flask Adapters Can Streamline the Cell Culturing Process”
“MIT-based startup nabs $30M for first 3-D printed drug approved by FDA,” Fierce Biotech
“This spring, Aprecia Pharmaceuticals launched the first 3-D printed pharmaceutical product to be approved by the FDA. It’s now secured $30 million in debt to aid that launch and bring forward more 3-D printed fast-melt formulations.”
If you like this story, please see our blog titled “Cool Tool – Off the Shelf Optimized CHO Media and Feed”
“Unmasking Alzheimer’s risk in young adults,” CNN
The risk for developing devastating Alzheimer’s disease may be detectable in healthy adults younger than expected, and new studies reveal how.”
If you like this story, please see our blog titled “New Poster: Proving Clonality – A Documented Clonality Report for Regulatory Submission”
“Men With Advanced Prostate Cancer Might Consider Gene Test,” US News and World Report
“Men with prostate cancer that has spread to other parts of their body should be considered for genetic testing, a new study suggests.”
If you like this story, please see our blog titled “Cell Culture and Single Cell Passaging of Human Pluripotent Stem Cells Without the Need for ROCK Inhibitor”